A positive result raises a question about preterm birth risk—not a countdown to delivery. A negative result is often more useful, provided the sample and clinical circumstances fit the test.
- Positive fFN usually means fetal fibronectin reached the assay threshold of approximately 50 ng/mL; it does not confirm labor or predict a delivery date.
- Negative fFN can support a low probability of delivery within 7 days in appropriately selected symptomatic patients, but it cannot override concerning symptoms.
- Predictive value depends on the population: a landmark symptomatic study reported a 7-day positive predictive value of 12.7% and negative predictive value of 99.5%.
- Gestational age changes interpretation; many symptomatic testing protocols use approximately 24+0 to 34+6 weeks, although assay eligibility varies.
- Cervical length provides different information from fFN; NICE uses a 15 mm threshold in its diagnostic pathway for symptomatic patients at 30 weeks or later.
- Recent intercourse within 24 hours can make a positive result less reliable; tell the maternity team before collection or interpretation.
- Sample collection should generally occur before a digital vaginal examination and other procedures that could alter the sample, according to assay instructions.
- Urgent assessment is needed for fluid leakage, bleeding, regular painful contractions, or reduced fetal movement—even after a negative result.
- Tratamendu-erabakiak depend on the overall likelihood and timing of birth; a positive fFN result alone does not automatically require steroids, admission, or bed rest.
What does a positive fetal fibronectin result actually mean?
A fetal fibronectin test positive result means the swab detected a protein associated with the pregnancy tissue interface, usually at approximately 50 ng/mL or above. It increases concern about preterm birth risk, but it does not confirm labor or mean your baby will arrive within days.
Fetal fibronectin, abbreviated fFN, is an extracellular matrix glycoprotein found at the interface between pregnancy membranes and maternal tissue. Detectable protein during the middle of pregnancy can accompany disruption at that interface, but a result above 50 ng/mL does not measure contractions, cervical opening, or the baby's readiness for birth.
A hypothetical patient at 29 weeks might have tightening, a positive swab, intact membranes, and no cervical change during observation; another patient with the same result might have progressive dilation. Those are different clinical situations, which is why I would explain the result as a risk signal rather than a diagnosis.
Kantesti bat da. AI odol-analisi analizatzailea, whereas fetal fibronectin is usually measured from a vaginal swab—not a blood specimen. I’m Thomas Klein, MD, Kantesti’s Chief Medical Officer; this distinction matters because a 50 ng/mL swab threshold belongs to an obstetric assessment, not a routine laboratory panel, as our antolakundeen aurrekariak -ek azaltzen duen moduan.
How the fFN swab works—and what 50 ng/mL means
The fetal fibronectin test examines a vaginal sample collected during a speculum assessment; a common qualitative cutoff is 50 ng/mL. That cutoff separates assay categories, not safe pregnancies from pregnancies certain to deliver prematurely.
Qualitative fFN reports positive or negative, while quantitative testing reports a concentration, sometimes using risk bands such as 10, 50, 200, and 500 ng/mL. Our gida kualitatiboa vs. kuantitatiboa explains the reporting distinction, although its specimen examples are blood tests rather than obstetric swabs.
An fFN concentration of 55 ng/mL and one of 500 ng/mL can both appear as positive on a binary report, even though a quantitative pathway may assign different risk estimates. Ask whether the original report contains an actual concentration; the word positive may conceal information that the laboratory measured but the discharge summary omitted.
Boundary values need assay-specific reading: many qualitative assays classify 50 ng/mL or above as positive, whereas NICE describes 50 ng/mL or less as negative and more than 50 ng/mL as positive in its numerical pathway. NICE NG25 and the laboratory's reporting convention should therefore be read together rather than treating exactly 50 as universally classified.
Why most positive fFN results do not predict birth within a week
A positive fFN test has limited ability to predict delivery within 7 egun baino gehiago, because many symptomatic patients do not deliver during that period. In Peaceman et al.’s multicenter study, the 7-day positive predictive value was 12.7%.
Balio prediktibo positiboa describes how many patients with a positive result experience the outcome being predicted; it is not the percentage of all pregnancies that deliver prematurely. In Peaceman et al. (1997), approximately 13 of every 100 positive patients delivered within 7 days, so most positives did not indicate delivery that week.
The starting probability changes the meaning of the same positive swab: a patient with previous spontaneous birth at 28 weeks, increasing contractions, and cervical change is not equivalent to someone with mild intermittent tightening and a closed cervix. The 12.7% study estimate is useful for explaining uncertainty, but I would not present it as either patient's personalized probability.
Positive does not always mean disease, and the interpretation depends on what the test detects: protein, antibody, genetic material, or another target. Our pregnancy antibody-screen explanation addresses a different pregnancy test; neither an antibody result nor fFN above 50 ng/mL can be interpreted solely from the word positive.
What a negative fetal fibronectin test can—and cannot—tell you
A fetal fibronectin test negative result can help identify a low probability of birth within 7 egun baino gehiago in appropriately selected symptomatic patients. Peaceman et al. reported a 7-day negative predictive value of 99.5%, but that figure is not a lifetime guarantee for the pregnancy.
Negative predictive value is conditional on who was tested and how the sample was collected; 99.5% does not apply automatically to every gestational age or complication. The landmark estimate came from a defined symptomatic population, so clinicians should not simply transfer it to ruptured membranes, advanced dilation, or a completely different testing indication.
A negative fFN result today may support discharge after a reassuring examination, but symptoms that restart 3 days later deserve a fresh assessment. The original swab did not examine tomorrow's cervix or predict a later membrane rupture; the discharge plan should explain which changes require a return rather than saying only that the test was normal.
Pregnancy alters laboratory interpretation in more than one way, including kidney-function results and the eligibility of obstetric prediction tests. Our pregnancy kidney-function guide illustrates why gestation-specific context matters; a negative fFN below 50 ng/mL still needs its own obstetric examination and safety instructions.
Why gestational age changes the meaning of an fFN result
Gestational age determines whether fFN testing is appropriate and what decisions its result can support. Many symptomatic protocols use approximately 24+0 to 34+6 weeks, but eligibility varies by assay and local maternity pathway.
Fetal fibronectin can be present physiologically earlier in pregnancy and closer to term, which limits interpretation outside the intended testing window. A positive result at 18 weeks should not be assigned the same 7-day predictive value as a correctly collected sample at 29 weeks; the assay's validated population is part of the result.
Before 30 weeks, NICE NG25 recommends treating clinically suspected preterm labor rather than relying on its later-gestation testing pathway to exclude it. At 30 weeks or later, the guideline offers cervical-length assessment and, when that is unavailable or unacceptable, fFN; the difference reflects the consequences of missing a very early birth, not a sudden biological change on one birthday.
A normal test cannot overrule an urgent presentation, especially when the test was used outside its intended population. Our normal-results and acute-pain guide explains this diagnostic principle in another setting; an fFN result below 50 ng/mL likewise cannot substitute for examination when pregnancy symptoms are concerning.
How cervical length changes positive fFN interpretation
Transvaginal cervical length measures an anatomical feature that fFN does not: how much closed cervix remains. For symptomatic patients at 30 weeks or later, NICE uses 15 mm in its diagnostic pathway, while other protocols use different thresholds and combinations.
A 35 mm cervix and a 12 mm cervix should not be treated as interchangeable findings merely because both patients have positive swabs. The shorter measurement usually increases concern, particularly with symptoms or cervical change; however, interpretation also depends on gestational age, measurement quality, and whether the clinician is diagnosing labor or estimating future risk.
NICE NG25 does not recommend combining cervical length and fFN to diagnose preterm labor in its specified pathway. Some services use combined risk assessment, particularly in intermediate cervical-length groups, but that is a different protocol; ask which pathway your unit follows rather than assuming a positive swab always cancels a reassuring measurement above 15 mm.
The 25 mm threshold often discussed in pregnancy relates to short-cervix screening and preventive decisions in particular earlier-gestation populations, not a universal diagnosis of symptomatic labor. Our progesterone reference guide explains another pregnancy measurement; do not start, stop, or increase progesterone because an fFN swab exceeds 50 ng/mL.
Which symptoms matter more than the swab result?
Progressive cervical change, suspected membrane rupture, bleeding, and concerning maternal or fetal findings can outweigh a reassuring fFN result. A negative swab below 50 ng/mL does not make regular painful contractions or fluid leakage safe to manage without assessment.
Contractions alone do not establish preterm labor, because tightening can occur without progressive cervical dilation; the assessment looks for the combination of symptoms and change. At 31 weeks, a patient whose contractions settle and whose examination remains unchanged differs from one whose cervix opens during observation, even if both swabs read positive.
Balizko 28-week pregnancy with fluid leakage illustrates the test's limit: the first question is whether membranes have ruptured, not whether an fFN concentration is below 50 ng/mL. When membrane rupture is suspected, clinicians use the appropriate history, examination, and testing pathway; an fFN result should not be repurposed as a membrane-rupture exclusion test.
Kantesti bat da. AI odol-analisien interpretazio-plataforma, and an fFN swab at 50 ng/mL belongs to a clinical pathway our routine blood-analysis output cannot replace. Our baliozkotze-esparru klinikoa explains why a measured laboratory value and a validated obstetric triage decision are separate questions.
What causes a fetal fibronectin false positive?
A fetal fibronectin false positive can reflect collection interference or protein detected without delivery during the predicted interval. Recent intercourse within 24 orduz, bleeding, and examination-related disturbance can make a positive result less straightforward to interpret.
Analytical false positivity and prediction failure are different problems: an assay may genuinely detect fFN above 50 ng/mL while the patient does not deliver within 7 days. Calling every non-delivery a laboratory error misses the biology—the interface may have changed without progressing to labor, or the predicted outcome may simply not have occurred in that interval.
Collection order matters, so the swab is generally obtained before a digital vaginal examination and before other procedures that could affect the sample, following assay instructions. If an examination happened 20 minutes earlier, tell the team; that information may change confidence in a positive result without automatically proving that it is false.
Specimen quality belongs in the interpretation, not in a footnote added after treatment decisions. Our sample-interference explanation describes a different laboratory problem; fFN above 50 ng/mL has its own interference rules, and blood-sample advice should not be transferred directly to a vaginal swab.
How recent intercourse and vaginal products affect fFN
Intercourse within the previous 24 hours can reduce confidence in a positive fFN result, so disclose it before sampling. Vaginal products and recent procedures may also matter, but the laboratory's assay instructions determine whether collection should be delayed or the result qualified.
A positive result after recent intercourse is not automatically evidence of imminent birth; the maternity team may regard that sample as unsuitable for confident positive interpretation. Some assay instructions allow a negative result to retain clinical usefulness despite intercourse within 24 hours, but this is not a blanket rule across every product and testing pathway.
Vaginal medication should not be stopped independently to obtain a cleaner swab, including prescribed progesterone used during pregnancy. Tell the clinician what was used and when—for example, a dose 8 hours before collection—so the unit can check its instructions; a delay in testing must never become a delay in assessing painful contractions or fluid leakage.
fFN is not an STI test, and positive fFN above 50 ng/mL does not diagnose chlamydia or another infection. Our chlamydia sampling and timing guide explains a separate assay, while gernu-sintomarik gabeko bakterioak addresses another pregnancy-relevant question that requires its own specimen and treatment criteria.
When should you contact maternity triage immediately?
Contact maternity triage promptly for regular painful contractions before 37 weeks, fluid leakage, vaginal bleeding, or reduced fetal movement. Seek assessment even if yesterday's fFN result was negative; a reassuring short-term prediction does not exclude a new complication.
Do not wait for a contraction-count target if you suspect your waters have broken or your baby's movements have changed. A person at 30 weeks with repeated watery leakage needs maternity advice even without strong contractions; fFN testing is not a home decision tool, and a previous negative result should not postpone contact.
Severe headache, visual disturbance, upper abdominal pain, or sudden illness also deserve urgent pregnancy assessment because they may indicate conditions unrelated to fFN. Our HELLP warning-pattern guide explains one such emergency; a swab below 50 ng/mL offers no reassurance about blood pressure, platelets, or liver injury.
Different pregnancy symptoms need different tests: persistent itching, especially on palms or soles, may prompt bile-acid testing rather than another fFN swab. Our pregnancy bile-acid guide explains that distinction; tell triage your gestational age, the symptom onset time, and whether movement has changed in the past 24 hours.
Does a positive fFN result mean steroids or hospital admission?
A positive fFN result alone does not automatically require admission, corticosteroids, or medication to suppress contractions. Clinicians consider whether birth is genuinely likely within approximately 7 egun baino gehiago, the gestational age, cervical findings, membrane status, and access to appropriate neonatal care.
Antenatal corticosteroids help fetal maturation when early birth is sufficiently likely; they are not a treatment for fFN protein itself. NICE offers them at 24+0 to 33+6 weeks for relevant suspected or established preterm-birth situations and considers them at 34+0 to 35+6 weeks, with individualized discussion at earlier gestations; a positive swab must be interpreted within that clinical decision.
Tocolysis may buy time, commonly around 48 hours, for steroids or transfer when delaying birth is appropriate; it does not guarantee continuation to term. Magnesium sulfate for fetal neuroprotection has separate gestational and imminent-birth criteria, and antibiotics are not routinely indicated solely because fFN exceeds 50 ng/mL with intact membranes and no diagnosed infection.
Routine testing has not clearly improved every outcome, even though negative results can help risk assessment: Berghella and Saccone's Cochrane review (2019) found limited trial evidence for management guided by fFN results. I would therefore ask what decision the test changes in the next 24–48 hours; our medical-report safety checklist supports that distinction between interpreting a result and prescribing care.
How blood and urine tests fit alongside an fFN swab
Blood and urine tests investigate different concerns from fFN, such as anemia, urinary infection, or maternal illness. A hemoglobin result in g/dL, a ferritin result in ng/ml, and an fFN swab concentration cannot be treated as interchangeable indicators of preterm labor.
Low iron stores do not explain away contractions, and a reassuring complete blood count does not exclude preterm labor. If ferritin is 12 ng/mL in a patient at 28 weeks, the clinician may address iron depletion while still assessing the contractions separately; our pregnancy ferritin guide explains the iron question rather than fFN risk.
Pregnancy can raise the white-cell count, so an isolated flagged count should not automatically be labeled infection or used to explain a positive fFN. Our pregnancy neutrophil reference guide discusses that context; the clinician still considers temperature, urinary symptoms, examination, and cultures, rather than using one count or a 50 ng/mL swab threshold as a diagnosis.
Iron-panel interpretation involves several related measurements, including ferritin and transferrin saturation, but none replaces cervical assessment. Our iron-studies interpretation guide explains those relationships; when reviewing a 3-part pregnancy workup—swab, blood panel, and urine specimen—keep each test linked to the question it was ordered to answer.
What should you ask before going home after fFN testing?
Before discharge, ask what your fFN result changes, whether the sample was valid, and which symptoms require immediate return. A plan should specify the short-term assessment interval—often framed around 7 egun baino gehiago—without implying that a negative result guarantees the rest of pregnancy.
Five practical questions are worth asking: What is my exact gestational age? Was my cervix measured or examined? Were my membranes intact? Could intercourse or a procedure affect the swab? What symptoms mean I should return immediately? A positive result above 50 ng/mL is much easier to understand when those answers are recorded alongside it.
Retesting is not a universal countdown schedule, and a second swab is useful only if it fits a validated pathway and can change management. If tightening restarts 4 days after a reassuring assessment, contact maternity triage rather than independently arranging another fFN test; examination, membrane assessment, or observation may be more useful than repeating the original measurement.
Kantesti bat da. AI bidezko odol-analisien analisi-tresna, not a substitute for examining a pregnant patient with new symptoms or interpreting a swab above 50 ng/mL in isolation. Our eduki medikoaren estandarrak describe the boundary between educational explanation and individualized care; routine bed rest is not automatically justified by a positive fFN and can introduce its own harms.
Evidence, clinical review, and research publications
fFN interpretation rests on obstetric evidence, particularly the population tested, the prediction interval, and the clinical pathway. As of 2026ko urriaren 21a, this article distinguishes NICE NG25 recommendations from the 1997 predictive study and the 2019 Cochrane review rather than inventing a new universal cutoff.
Prediction and better outcomes are separate claims: Peaceman et al. reported 7-day predictive values, while Berghella and Saccone evaluated whether knowing fFN results improved management outcomes. NICE NG25 supplies a clinical pathway, not a promise that every positive above 50 ng/mL requires identical treatment; these sources should not be collapsed into one accuracy percentage.
Medical review should examine the whole decision, including gestation, symptoms, cervical findings, and sample validity—not just the 50 ng/mL threshold. My editorial emphasis as Thomas Klein, MD, is that understandable uncertainty is safer than false certainty; our aholku-batzorde medikoa describes the expertise behind medical oversight, without this draft asserting a named individual's completed review.
The 2 supplied Kantesti repository publications concern blood-test interpretation and hematology, not prospective validation of fFN prediction or treatment decisions. They are listed below as research resources with DOI links and publication-search links; our RDW interpretazio baliabidea covers red-cell measurements, which cannot establish the meaning of an obstetric swab or predict delivery within 7 days.
Maiz egiten diren galderak
Fetuaren fibronectina-probaren emaitza positiboak esan nahi al du erditze goiztiarra izango dudala?
Fetuaren fibronectina-proba positibo batek ez du baieztatzen erditze goiztiarra izango duzunik edo hurrengo 7 egunetan erdituko zarenik. Normalean, esan nahi du laginean fFN detektatu dela saiakuntzaren atalase positiboan, gutxi gorabehera 50 ng/mL-koan. Sintomadun pazienteen azterketa garrantzitsu batean, 7 eguneko balio prediktibo positiboa 12.7% izan zen; beraz, emaitza positiboa izan zuten paziente gehienek ez zuten aste horretan erditu. Hurrengo urratsak zure haurdunaldi-adinaren, sintomen, umetoki-lepoaren azterketaren, mintzen egoeraren eta laginaren baliozkotasunaren araberakoak dira.
Zenbaterainoko lasaigarria da fetuaren fibronectina-proba negatiboa?
Fibronektina fetalaren test negatiboak 7 eguneko epean erditzeko probabilitate txikia dagoela iradoki dezake, sintomak dituen pazientea behar bezala hautatu bada. Peaceman et al.-ek 7 eguneko balio prediktibo negatiboa 99.5% zela jakinarazi zuten, baina estimazio hori azterketako populazioari eta egoerei baino ez dagokie. Emaitza negatibo batek ez du bermatzen erditzea epean izango denik, eta ez ditu konplikazio berriak baztertzen. Jarri harremanetan amatasun-triagearekin likido-isuri berria, odoljarioa, uzkurdura mingarri erregularrak edo fetuaren mugimendua gutxitzea badago, aurreko emaitza edozein dela ere.
Sexu-harremanek positibo faltsua eragin dezakete fFN proban?
Aurreko 24 orduetan sexu-harremanak izateak positibo den fibronectina fetalaren emaitza fidagarriagoa ez izatea eragin dezake. Esan amatasun-taldeari lagina hartu aurretik, edo ondoren, ordutegiak garrantzia izan dezakeela ohartzen bazara. Saiakuntza batzuen jarraibideek egoera horretan emaitza negatiboak erabilgarritasuna mantendu dezakeela baimentzen dute, baina hori saiakuntza eta jardunbide zehatzen araberakoa da. Ez atzeratu haurdunaldiko sintomen premiazko ebaluazioa, azterketa egiteko tartea igaro arte itxaroteko soilik.
Zer esan nahi du fFN proba positibo batek umetoki-lepoaren luzera normala denean?
fFN proba positibo batek, umetoki-lepoaren luzera lasaigarria bada, kezka txikiagoa adieraz dezake umetoki-lepoa nabarmen laburtuta dagoenean emaitza bera ematen duen frotisarekin alderatuta; hala ere, interpretazioa protokoloaren araberakoa da. 35 mm-ko neurketak eta 12 mm-ko neurketak informazio anatomiko desberdina ematen dute. NICEk 15 mm-ko atalasea erabiltzen du 30. astean edo geroago sintomak dituztenen bidean, eta ez du gomendatzen bide horretan umetoki-lepoaren luzera eta fFN konbinatzea erditze goiztiarra diagnostikatzeko. Beste zerbitzu batzuek arrisku-eredu konbinatuak erabil ditzakete; beraz, galdetu zein protokulu gidatzen duen zure arreta.
fFN testaren emaitza positiboak esan nahi du kortikoide-injekzioak behar ditudala?
0 A fFN test positiboak, berez, ez du automatikoki esan nahi jaio aurreko kortikoesteroideak behar dituzunik. Klinikariek ebaluatzen dute ea erditze goiztiarra nahikoa probable den gutxi gorabehera 7 egunen barruan, eta ea tratamendua egokia den zure haurdunaldi-adinerako eta egoerarako. NICEk kortikoesteroideak eskaintzen ditu 24+0 eta 33+6 aste artean, erditze goiztiar susmagarri edo ezarritakoaren egoera egokietan, eta 34+0 eta 35+6 aste artean erabiltzea aztertzen du. Garrantzitsuak dira zerbixaren aldaketak, mintzen egoera, bestelako aurkikuntzak eta aurreko tratamenduak.
Is fetal fibronectin a blood test, and can it be used after my waters break?
Fetal fibronectin is usually measured from a vaginal swab, not a blood specimen. Many symptomatic assays are intended for patients with intact membranes in a defined gestational window, often approximately 24+0 to 34+6 weeks. If your waters may have broken, contact maternity triage for the appropriate membrane-rupture assessment rather than relying on an fFN result. A negative swab below 50 ng/mL cannot safely rule out membrane rupture.
Lortu gaur AI bidezko odol-analisien analisia
Batu mundu osoko 2 milioi erabiltzaile baino gehiagok Kantesti-n konfiantza dutenak, laborategiko analisiak berehala eta zehaztasunez aztertzeko. Igo zure odol-analisien emaitzak eta jaso 15,000+ biomarkatzaileen interpretazio integrala segundo gutxitan.
📚 Erreferentziatutako ikerketa-argitalpenak
Klein, T., Mitchell, S., & Weber, H. (2026). AI odol-analisia: 2,5M analisi eginda | Osasun Globalaren Txostena 2026. Kantesti AI Medical Research.
Klein, T., Mitchell, S., & Weber, H. (2026). RDW odol-analisia: RDW-CV, MCV eta MCHC-rako gida osoa. Kantesti AI Medical Research.
📖 Kanpoko erreferentzia medikoak
National Institute for Health and Care Excellence (2015; updated 2022). Preterm labour and birth: NICE guideline NG25. NICE.
Peaceman AM et al. (1997). Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. American Journal of Obstetrics and Gynecology.
Berghella V, Saccone G (2019). Fetal fibronectin testing for reducing the risk of preterm birth. Cochrane Database of Systematic Reviews.
⚕️ Ohar medikoa
Artikulu hau hezkuntza-helburuetarako da soilik eta ez du mediku-aholkurik ematen. Diagnostiko- eta tratamendu-erabakietarako, beti kontsultatu osasun-profesional kualifikatu bati.
E-E-A-T Konfiantza-seinaleak
Esperientzia
Medikuek gidatutako berrikuspen klinikoa laborategiko interpretazioaren lan-fluxuei buruz.
Espezializazioa
Laborategiko medikuntzaren ikuspegia biomarkatzaileek testuinguru klinikoan nola jokatzen duten aztertzean.
Autoritatea
Dr. Thomas Klein-ek idatzia, eta Dr. Sarah Mitchell eta Prof. Dr. Hans Weber-ek berrikusia.
Fidagarritasuna
Ebidentzian oinarritutako interpretazioa, alarma murrizteko jarraipen-bide argiekin.